Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zer, Alona
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)	Recruiting	3	170	Europe, Canada, Japan, US, RoW	Selpercatinib, LY3527723, LOXO-292, Placebo	Loxo Oncology, Inc., Eli Lilly and Company	Carcinoma, Non-Small-Cell Lung	05/27	08/32
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors	Active, not recruiting	2/3	192	Europe, US, RoW	AL102, Placebo	Ayala Pharmaceuticals, Inc,	Desmoid, Desmoid Tumor	01/25	02/25
NCT05127590: RBN-2397 in Combination With Pembrolizumab in Patients With SCCL	Active, not recruiting	1b/2	50	Europe, US, RoW	RBN-2397, Pembrolizumab, Keytruda	Ribon Therapeutics, Inc.	Advanced Squamous Non-Small Cell Lung Carcinoma	11/23	12/23
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments	Recruiting	N/A	2000	Europe, US, RoW	Plasma sample collection	OncoHost Ltd.	Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma	10/29	10/29